Maxim Group Begins Coverage on KindlyMD (NASDAQ:NAKA)

Key Points

• Maxim Group has initiated coverage on KindlyMD (NASDAQ:NAKA) with a "buy" rating and a price target of $8.00, suggesting a potential upside of 72.79% from the current stock price.
• KindlyMD has reported a negative EPS of ($0.34) in its latest quarterly earnings and generated revenue of only $0.41 million.
• The company focuses on holistic pain management and aims to address the opioid epidemic through integrated healthcare solutions.

Maxim Group assumed coverage on shares of KindlyMD (NASDAQ:NAKA - Get Free Report) in a note issued to investors on Wednesday,Briefing.com Automated Import reports. The brokerage set a "buy" rating and a $8.00 price target on the stock. Maxim Group's price objective indicates a potential upside of 72.79% from the stock's current price.

KindlyMD Price Performance

Shares of NAKA opened at $4.63 on Wednesday. KindlyMD has a 1-year low of $0.65 and a 1-year high of $34.77. The stock has a market capitalization of $1.74 billion, a P/E ratio of -5.38 and a beta of 33.96. The company has a 50 day moving average of $10.62.

KindlyMD (NASDAQ:NAKA - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported ($0.34) EPS for the quarter. The company had revenue of $0.41 million during the quarter. KindlyMD had a negative return on equity of 131.09% and a negative net margin of 244.00%.

KindlyMD Company Profile

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.